Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PF-07976016 + liraglutide
- Development stage
- Discontinued
- Modality
- Small Molecules, Peptides
- Administration
- Oral, Subcutaneous
01
Overview
**PF-07976016 + liraglutide** is an investigational combination regimen consisting of PF-07976016, an orally bioavailable small-molecule antagonist of the gastric inhibitory polypeptide receptor (GIPR), and liraglutide, a subcutaneous peptide agonist of the glucagon-like peptide-1 receptor (GLP-1R). Developed by Pfizer, PF-07976016 was designed as a first-in-class selective small-molecule GIPR antagonist to evaluate whether blocking GIPR signaling could provide additive weight loss when combined with GLP-1R agonism. The combination was evaluated in a Phase 2a clinical trial (NCT06717425) for the treatment of adults with obesity. However, in August 2026, Pfizer announced the discontinuation of PF-07976016's development following a review of the Phase 2a data on the liraglutide background.
- Other names
- PF-07976016 and liraglutidePF07976016 and liraglutidePF 07976016 and liraglutideliraglutide + PF-07976016
02
Targets
GIPR (Gastric inhibitory polypeptide receptor)GLP1R (GLP-1R)
Beyond the preview
Go deeper on PF-07976016 + liraglutide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PF-07976016 + liraglutide.